To evaluate the potential for combination therapy and overcome the limitations of monotherapy in HER2-positive breast cancer, T47D cells were treated with 17-AAG-loaded PEG-CS NPs, trastuzumab (10 μg/mL), or their combination. This evidence concerns the gene ERBB2 and breast cancer.